Sarah C Garrett-Thomson
Overview
Explore the profile of Sarah C Garrett-Thomson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morano N, Smith R, Danelon V, Schreiner R, Patel U, Herrera N, et al.
J Clin Invest
. 2022 Sep;
132(22).
PMID: 36107635
Cell surface receptors, ligands, and adhesion molecules underlie development, circuit formation, and synaptic function of the central nervous system and represent important therapeutic targets for many neuropathologies. The functional contributions...
2.
Korman A, Garrett-Thomson S, Lonberg N
Nat Rev Drug Discov
. 2022 Jan;
21(2):163.
PMID: 35031767
No abstract available.
3.
Korman A, Garrett-Thomson S, Lonberg N
Nat Rev Drug Discov
. 2021 Dec;
21(7):509-528.
PMID: 34937915
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific discussion and experimentation for over a hundred years. Several successful cancer immunotherapies - such as IL-2 and...
4.
Liu W, Chou T, Garrett-Thomson S, Seo G, Fedorov E, Ramagopal U, et al.
J Exp Med
. 2021 Oct;
218(12).
PMID: 34709351
HVEM is a TNF (tumor necrosis factor) receptor contributing to a broad range of immune functions involving diverse cell types. It interacts with a TNF ligand, LIGHT, and immunoglobulin (Ig)...
5.
Herrera N, Morano N, Celikgil A, Georgiev G, Malonis R, Lee J, et al.
ACS Omega
. 2021 Jan;
6(1):85-102.
PMID: 33458462
Coronavirus disease 2019 (COVID-19) is a global health crisis caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and there is a critical need to produce large quantities...
6.
Shrestha R, Garrett-Thomson S, Liu W, Almo S, Fiser A
Structure
. 2020 Aug;
28(11):1197-1205.e2.
PMID: 32795404
Herpes virus entry mediator (HVEM) regulates positive and negative signals for T cell activation through co-signaling pathways. Dysfunction of the HVEM co-signaling network is associated with multiple pathologies related to...
7.
Herrera N, Morano N, Celikgil A, Georgiev G, Malonis R, Lee J, et al.
bioRxiv
. 2020 Jun;
PMID: 32587972
Coronavirus disease 2019 ( ) is a global health crisis caused by the novel severe acute respiratory syndrome coronavirus 2 ( ), and there is a critical need to produce...
8.
Garrett-Thomson S, Massimi A, Fedorov E, Bonanno J, Scandiuzzi L, Hillerich B, et al.
PLoS One
. 2020 Jun;
15(6):e0233578.
PMID: 32497097
The B7 family represents one of the best-studied subgroups within the Ig superfamily, yet new interactions continue to be discovered. However, this binding promiscuity represents a major challenge for defining...
9.
Smith E, Harrington K, Staehr M, Masakayan R, Jones J, Long T, et al.
Sci Transl Med
. 2019 Mar;
11(485).
PMID: 30918115
Early clinical results of chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) for multiple myeloma (MM) appear promising, but relapses associated with residual low-to-negative BCMA-expressing...
10.
Smith E, Staehr M, Masakayan R, Tatake I, Purdon T, Wang X, et al.
Mol Ther
. 2018 Apr;
26(6):1447-1456.
PMID: 29678657
B cell maturation antigen (BCMA) has recently been identified as an important multiple myeloma (MM)-specific target for chimeric antigen receptor (CAR) T cell therapy. In CAR T cell therapy targeting...